Menu
Investors in BioNTech or Pfizer have invested and recently suffered a damper. On November 9, 2020, the companies announced that their corona vaccine was ready and was only waiting for an examination by the FDA ( Food and Drug Administration ). However, there is another candidate in the race for the best and most effective vaccine: Curevac.
The biopharmaceutical company from Tübingen enters the race with a big plus. On November 12 November 2020, the company announced that their vaccine was not only successful but could also be kept in the refrigerator for up to 3 months. The cooling requirements are, therefore, a great advantage over the competitors.
Accordingly, there is a great question among investors as to whether it is worth investing in shares of Curevac. Is now the right time to start? How will Curevac develop? We cover the basic data on the Curevac share: price, reviews, prospects, analysis, forecasts, recommendations, history and tips on how and where to buy Curevec shares online easily.
You should pay attention to the following points when buying Curevac shares:
Rating
Min. Deposit
Min. Spread
Assets
Views
Positive Reviews
Negative Reviews
Likes
In order to be able to buy the Curevac share, you first have to register and log in with a broker of your choice. In order to be able to buy a share, you always need a broker who buys the share on the market and then holds it in custody. It is advisable to pay particular attention to deposit protection. Should the broker file for bankruptcy, the shares still belong to you. Anyone who waives this deposit protection will be left without shares in the event of the broker’s bankruptcy.
If stock selection and evaluation are too complicated, a social trading platform can also be a good solution. Here you simply follow an experienced trader and automatically copy the trader’s trading decisions.
Our broker recommendation at this point is Capixal – with state-guaranteed deposit protection of up to 20,000 euros and 0% commission when buying shares, Capixal is our test winner broker. To register with Capixal, click here.
If you have decided on a broker, you log in with your data and verify your email address and other data.
After registering, you need to decide how much to invest in stocks. We generally recommend that you never invest more than 5% of your capital in a single share.
Once you have decided on the amount you want to invest, click the ” Add Money ” button.
You can now choose from various deposit methods, including PayPal, credit card or bank transfer. It should be noted that a bank transfer usually takes 2-3 working days for the credit to arrive on the customer account. However, if you want to have your money in your account faster, other payment methods are available.
Below is an overview of all the payment methods available at Capixal:
| Payment option | Possible? |
| Buy Curevac shares with a credit card | ✔️ |
| Buy Curevac shares with PayPal | ✔️ |
| Buy Curevac shares with Skrill | ✔️ |
| Buy Curevac shares by bank transfer | ✔️ |
| Buy Curevac shares with Neteller | ✔️ |
| Buy Curevac shares with UnionPay | ✔️ |
After the deposit, the money appears in your account under the menu item “Account”. First, find the Curevac share using the search bar above and select it. Then click on the “Trade” button.
A small window will open where you can set the price and the number of shares you want to buy. You can also set stop-loss and take-profit, i.e. at which price the share should be sold again in the event of a profit or loss. The two fields are optional.
With the field Leverage, you can buy a “real share” with single leverage or a CFD (with double or multiple leverages).
The purchase is completed with a click on “Place order,” and the share appears in your portfolio.
Curevac NV is a biopharmaceutical company with legal headquarters in the Netherlands. The headquarters of the company is located in Tuebingen. The company was founded in 2000 and currently employs 500 people. The annual turnover in 2019 was EUR 17.4 million.
The company specializes in the research and development of drugs based on the messenger molecule mRNA. Thus, Curevac is mainly dedicated to cancer patients. In 2019, it was announced that the vaccine alliance CEPI and Curevac had reached an agreement worth US $ 34 million. This should enable a quick supply of RNA vaccines against already known diseases such as Lassa fever, yellow fever and rabies.
At the end of January 2020, Curevac received another grant from CEPI in the amount of EUR 8.3 million for the development of a vaccine against COVID-19.
With its IPO on the US technology exchange Nasdaq, Curevac raised fresh money for the development of a corona vaccine. Initially, 13.33 million shares were issued at $ 16 each, adding $ 213 million to the company.
Like many young biotech companies, the Tübingen-based company needs money because development devours a lot of money and, without a market-ready product, income will only flow sparingly. For 2019, CureVac posted sales of 17.4 million euros and a loss of 99.9 million euros.
On Thursday, the Curevac climbed share on the NASDAQ by 12.51 per cent to 69.69 USD. The current price of the stock is US $ 74.64 (NASDAQ). The price is currently trading at EUR 63.50 on the Frankfurt Stock Exchange (5CV) (as of November 19, 2020). When it went public, the price was EUR 62.90. The previous low was EUR 62.35, while the high was EUR 63.80.
The current price (as of March 16, 2021) for the Curevac share is € 78.00 on the Frankfurt trading venue and $ 92.85 on the NASDAQ in New York.
Since it was listed on the stock exchanges, the Curevac share has been able to generate huge profits for investors. At the Frankfurt Stock Exchange, the issue price in June 2020 was € 40.58 per share. To date, the share on the Frankfurt Stock Exchange has grown by 92%.
The stock first traded on NASDAQ in New York in August 2020 at a price of $ 55.90. With a current price of $ 92.85, the stock was able to achieve a growth of 66%. Therefore, investing in Curevac would have been an excellent investment.
The Curevac share is traded on both the NASDAQ in New York and the Frankfurt Stock Exchange. However, the two trading venues charge high fees for you as an investor for trading in Curevac shares.
We, therefore, recommend trading Curevac shares via Capixal due to the lower fees. Thanks to the lower trading fees and many years of experience in the market, Capixal is the right broker for you if you want to trade Curevac shares.
Curevac share analysis – What is the current position of the Curevac share
The share is currently at a price of € 78.00 (as of March 16, 2021) on the Frankfurt Stock Exchange and holds a lot of upside potential for you investors.
In June 2021, the approval of the vaccine against Covid-19 from Curevac is expected at the latest. It is precise because of this positive news that the share price of the Tübingen-based company could move upwards.
Not only with regard to vaccinations against COVID-19, but this approval would also mean significant progress. The approval would ultimately also confirm that the company can use mRNA technology to develop treatment methods against other diseases successfully. The potential in this area is almost limitless, and the technology is expected to be useful in the treatment of various cancers and rare diseases.
Therefore there is a lot of potential in the share, and in the current phase, the Curevac share could represent a good investment.
News and history of the Curevac share
The IPO of Curevac took place on August 14, 2020, at the American technology exchange Nasdaq. With an issue price of $ 16 and proceeds of $ 245 million, the company was valued at approximately $ 2.3 billion.
As part of the IPO, the former Curevac Aktiengesellschaft (AG) was converted into a Dutch public limited company, Curevac NV. At the same time, there was a capital increase of EUR 100 million.
After the IPO and additional financing by Dietmar Hopp (German entrepreneur and co-founder of the SAP company), the following shareholders held over 5%: Dievini Hopp BioTech Holding (49.5%), Kreditanstalt für Wiederaufbau (17.0%) and Glaxo (8.5%). Management boards and supervisory boards jointly hold 1.1%.
At the beginning of September, it was announced that Curevac would receive a grant of EUR 252 million from the federal government to accelerate the development of the corona vaccine.
The private bank Berenberg has left the rating for Curevac after a conference with the CEOs of BioNTech and Curevac at “Buy” with a target price of 72 euros. So things are looking perfect for the stock right now.
Should Curevac keep its promises, expectations would also be fulfilled. Curevac itself states that its active ingredient can be kept in the refrigerator for up to 3 months. Compared to Pfizer and BioNTech, this would be a huge advantage. Their vaccine must be stored and transported at -70 degrees Celsius. This would be a logistical nightmare. Should Curevac actually advance its vaccine, it would ensure the company an all-time high in 2021.
Most recently, the Curevac share started trading in Frankfurt and rose by 1.7 per cent to EUR 63.55. In the short term, the CureVac share reached its current high for the day at EUR 63.55. The share opened the trading session at EUR 62.90. Most recently, 3,264 CureVac shares changed hands.
With an average price target, the analysts’ forecasts for the CureVac share are EUR 72.00.
The competition never sleeps. Especially in times of the corona pandemic, more and more pharmaceutical companies are working on the development of a vaccine. Even if BioNTech and Pfizer have already applied to the FDA for approval, that doesn’t mean the vaccine will be a success. Another candidate for the vaccine is Moderna.
BioNTech, Pfizer and Moderna currently report 95% effectiveness. However, the cooling of the vaccines will play a big role. And here, Curevac is clearly ahead. This should be a disappointment if contrary to all expectations; the share may suffer a significant loss in value.
However, analysts and experts are currently recommending a clear buy of the share.
After the latest price gains, Curevac received a clear buy recommendation from Berenberg. The current target price is USD 72. Based on the current price level, this corresponds to around 20 per cent upside potential.
The forecasts point to a clear upward trend. However, even if BioNTech, Pfizer, or Moderna put their vaccine on the market first, that doesn’t mean Curevac will stop its study. Due to the current situation, there is an urgent need for further vaccines on the market. Because while pharmaceutical companies are constantly producing new reports of success in the search for a vaccine against Covid-19, politicians are trying to secure as much of the drugs as possible in advance.
Precisely because of this, Curevac received EU funding for the further development of its vaccine.
Since the IPO did not occur until August 2020, there is no data on the last or announced dividend.
The race for the corona vaccine is in full swing. Several pharmaceutical companies are currently working on a vaccine. Pfizer recently announced that it is already in the 3rd phase. The expectations are correspondingly high. So how does the Curevac share compare to the other pharmaceutical companies? Here is a brief overview:
We compare the fees of the largest brokers with the following example:
With these assumptions, we now compare the fees of Libertex, Capixal & Plus500 :
| Providers | Libertex | Capixal | Plus500 |
| Deposit | for free | free | for free |
| Purchase fees | € 2.20 | free | 3.08% |
| Holding fees | for free | free | 0.05% |
| Sales charges | € 2.20 | Spreads | 3.08% |
| Total fees | € 4.40 | Reasonable | € 92.32 |
One thing is clear: we need a corona vaccine. One company alone will not be enough here. Curevac is a relatively new pharmaceutical company that went public in August 2020, but the company is already expecting a lot.
The company announced that it is expanding its production of a vaccine. A European network is expected to produce up to 300 million doses in the coming year. Accordingly, Curevac works with several experienced partners in Europe.
Curevac also has a significant advantage over its competition. The vaccine should be able to be stored at only -5 degrees Celsius. This would make distribution and storage much easier.
Given the promising expectations, now is the right time to invest in the stock. Should Curevac keep its promises, shares could skyrocket in 2021. Investors, as well as analysts, are currently very optimistic.
With the encouraging data, the Curevac share has also jumped significantly ahead of the IPO. According to analyzes, all signs are currently pointing to BUY. Curevac only went public in August 2020, but the share has continued to gain since then. An investment could be worthwhile here.
Curevac has been listed on the largest electronic exchange, the American Nasdaq, since it went public. It is also listed on the Frankfurt Stock Exchange (5CV) and can be traded there.
The article introduces some ways in which you can quickly get hold of your own Curevac share. If you do not want to purchase the share directly, you also have the option of using CFDs to bet on rising or falling prices.
you can buy CureVac N.V. stock in any dollar amount, or any other fund or stock you know on Capixal
Investing is speculative. Your capital is at risk when investing. This website is not intended for use in any jurisdiction where the trading or investments described are prohibited and should only be used by persons and in a manner permitted by law. Your investment may not be eligible for investor protection in your country or state of residence. Therefore, conduct your own due diligence. This website is available to you free of charge, however we may receive commissions from the companies we offer on this website
Copyright © 2022 | securedbrokers
A trusted broker will contact you today.